Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease.

[1]  M. Corsi,et al.  Epicardial fat: from the biomolecular aspects to the clinical practice. , 2011, The international journal of biochemistry & cell biology.

[2]  G. Iacobellis,et al.  Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features , 2011, Trends in Endocrinology & Metabolism.

[3]  D. Mikhailidis,et al.  Regulation of Inducible Nitric Oxide Synthase (iNOS) and its Potential Role in Insulin Resistance, Diabetes and Heart Failure , 2011, The open cardiovascular medicine journal.

[4]  J. Leza,et al.  Cannabinoid/agonist WIN 55,212‐2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS , 2011, Diabetes/metabolism research and reviews.

[5]  M. Maccarrone,et al.  Energetic metabolism and human sperm motility: impact of CB₁ receptor activation. , 2010, Endocrinology.

[6]  A. Madan,et al.  Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat. , 2010, Metabolism: clinical and experimental.

[7]  Pál Pacher,et al.  Cannabinoid‐1 receptor activation induces reactive oxygen species‐dependent and ‐independent mitogen‐activated protein kinase activation and cell death in human coronary artery endothelial cells , 2010, British journal of pharmacology.

[8]  R. Sodian,et al.  Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. , 2010, Journal of molecular and cellular cardiology.

[9]  K. Mackie,et al.  CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. , 2010, Cardiovascular research.

[10]  H. Pan,et al.  Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. , 2010, Free radical biology & medicine.

[11]  S. Steffens,et al.  The emerging role of the endocannabinoid system in cardiovascular disease , 2009, Seminars in Immunopathology.

[12]  P. Caraceni,et al.  Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia–reperfusion injury complicated by endotoxaemia , 2009, Gut.

[13]  V. Marzo,et al.  Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors , 2009, Diabetologia.

[14]  Y. Izumiya,et al.  Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages , 2009, Circulation.

[15]  F. Uberti,et al.  Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial KATP channel , 2009, British journal of pharmacology.

[16]  G. Godlewski,et al.  Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. , 2008, Hypertension.

[17]  S. Verma,et al.  The endocannabinoid system and cardiometabolic risk. , 2008, Atherosclerosis.

[18]  V. Marzo.  The endocannabinoid system in obesity and type 2 diabetes , 2008, Diabetologia.

[19]  M. Sirois,et al.  Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. , 2007, Life sciences.

[20]  G. Ertl,et al.  2-Arachidonylglycerol Acting on CB1 Cannabinoid Receptors Mediates Delayed Cardioprotection Induced by Nitric Oxide in Rat Isolated Hearts , 2006, Journal of cardiovascular pharmacology.

[21]  Z. Vogel,et al.  Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production , 2006, Molecular and Cellular Biochemistry.

[22]  R. Bonser,et al.  Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease , 2006, Cardiovascular diabetology.

[23]  M. Gonthier,et al.  Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes , 2006, Histochemistry and Cell Biology.

[24]  Q. Feng,et al.  Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure. , 2005, Pharmacology & therapeutics.

[25]  V. Marzo,et al.  Endocannabinoid control of food intake and energy balance , 2005, Nature Neuroscience.

[26]  A. Rissanen,et al.  Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study , 2005, The Lancet.

[27]  M. Mocanu,et al.  Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. , 2005, American journal of physiology. Heart and circulatory physiology.

[28]  E. Okine,et al.  Primary Adipocyte Culture: Adipocyte Purification Methods May Lead to a New Understanding of Adipose Tissue Growth and Development , 2004, Cytotechnology.

[29]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[30]  B. Goldstein,et al.  Human Epicardial Adipose Tissue Is a Source of Inflammatory Mediators , 2003, Circulation.

[31]  B. Cravatt,et al.  Lipopolysaccharide Induces Anandamide Synthesis in Macrophages via CD14/MAPK/Phosphoinositide 3-Kinase/NF-κB Independently of Platelet-activating Factor* , 2003, Journal of Biological Chemistry.

[32]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[33]  D. Lamontagne,et al.  Endocannabinoids protect the rat isolated heart against ischaemia , 2003, British journal of pharmacology.

[34]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[35]  S. Batkai,et al.  Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. , 2001, European journal of pharmacology.

[36]  D. Lamontagne,et al.  Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide , 2001, British journal of pharmacology.

[37]  M. Glass,et al.  Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Augments cAMP Accumulation in Striatal Neurons: Evidence for a Gs Linkage to the CB1 Receptor , 1997, The Journal of Neuroscience.

[38]  S. Galiègue,et al.  Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. , 1995, European journal of biochemistry.

[39]  B. Cravatt,et al.  Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. , 2011, Free radical biology & medicine.

[40]  P. Pacher.  Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[41]  A. Molleman,et al.  Cannabinoid signalling (review) , 2006 .